Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;5(6):E254-307.
doi: 10.3978/j.issn.2072-1439.2013.11.28.

Guidelines for the diagnosis and treatment of malignant pleural mesothelioma

Nico van Zandwijk, Christopher Clarke, Douglas Henderson, A William Musk, Kwun Fong, Anna Nowak, Robert Loneragan, Brian McCaughan, Michael Boyer, Malcolm Feigen, David Currow, Penelope Schofield, Beth Ivimey Nick Pavlakis, Jocelyn McLean, Henry Marshall, Steven Leong, Victoria Keena, Andrew Penman
Review

Guidelines for the diagnosis and treatment of malignant pleural mesothelioma

Nico van Zandwijk et al. J Thorac Dis. 2013 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scenario A. The most common presentation of a patient with malignant mesothelioma. MPM, malignant pleural mesothelioma; VATS, video-assisted thoracoscopic surgery; TTNA, trans-thoracic needle aspiration; E(B)US, endoscopic bronchial ultrasound; FNA, fine needle aspiration.
Figure 2
Figure 2
Scenario B. Pathway of a patient presenting with pleural thickening or pleural mass. TTNA, trans-thoracic needle aspiration; MPM, malignant pleural mesothelioma; VATS, video-assisted thoracoscopic surgery.
Figure 3
Figure 3
Scenario C. The journey of the MPM patient with a pathologically confirmed diagnosis. MPM, malignant pleural mesothelioma; CT, computer tomography; PET, positron emission tomography; TNM, tumour, node, metastasis; MDT, multidisciplinary team.
Figure 4
Figure 4
Scenario D. Treatment choices for MPM patients after diagnosis and assessment.MPM, malignant pleural mesothelioma; MDT, multidisciplinary team; RT, radiotherapy.
Figure 5
Figure 5
Scenario E. Second-line treatment options. MPM, malignant pleural mesothelioma.
See this image and copyright information in PMC

References

    1. Procedures and requirements for meeting the 2011 NHMRC standard for clinical practice guidelines. version 1.1 ed. Melbourne: National Health and Medical Research Council, 2011.
    1. Leigh J, Driscoll T.Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003;9:206-17 - PubMed
    1. Musk AW, de Klerk NH. Epidemiology of malignant mesothelioma in Australia. Lung Cancer 2004;45Suppl 1:S21-3 - PubMed
    1. Mesothelioma in Australia Incidence 1982 to 2007 Mortality 1997 to 2007. Safe Work Australia, 2011:1-20. Available online: http://www.safeworkaustralia.gov.au/sites/swa/aboutsafeworkaustralia/wha...
    1. Henderson DW, Whitaker D, Shilkin KB. The differential diagnosis of malignant mesothelioma: a practical approach to diagnosis during life. In: Henderson DW, Shilkin KB, Langlois SLP, et al. eds. Malignant mesothelioma. New York: Hemisphere, 1992:184.